Skip to main content
. 2018 Dec 26;2018:9652817. doi: 10.1155/2018/9652817

Table 3.

CLINICAL data of representative MSCs therapy for IBD from Pubmed in the past decade.

  Sources Disease Therapeutic schedule Phase Number Evaluation Outcome Reference
1 Allogeneic-
BMMSCs		 UC a single dose of
(1.5-2) x 108 intravenously		 II 44 24 months 34 (72.7%) of patients achieved the clinical
and morphological indices of inflammatory activity↓.		 [112]
2 Allogeneic-
ADMSCs		 Perianal fistulizing CD a single dose of
1.2 x 108 intralesionally		 III 212 24 weeks 50% of patients treated with ADMSCs achieved combined remission. [113]
3 Allogeneic-
ADMSCs		 Perianal fistulizing CD a single dose intralesionally
If 2 x 107 failed, 4 x 107 subsequently		 II 24 24 weeks 69.2% of patients achieved the number of draining fistulas↓
56.3% of patients achieved complete fistula closure of the treated.
30% of patients achieved complete closure of all existing fistula tracts.		 [114]
4 Allogeneic-
BMMSCs		 Perianal fistulizing CD a single dose of 1 × 107,
3 × 107, or 9 × 107 intralesionally		 II 21 6, 12, and 24 weeks no severe adverse events.
3 × 107 MSCs appeared to promote healing of perianal fistulas		 [115]
5 Allogeneic-MSCs Luminal CD a single dose of
2 × 106 /kg weekly for
4 weeks intravenously		 II 16 42 days 15 patients CDAI score ↓ from 370 to 203 at day 42 [116]
6 Autologous-BMMSCs Luminal CD two doses of
1-2×106 intravenously,
7 days apart		 I 10 0, 6 weeks 3 patients CDAI score ↓ at 6 weeks [117]
7 Autologous-ADMSCs Perianal fistulizing CD local injection,2×107 I 12 24 weeks 9 of 12 patients had complete clinical healing by 3 months,
10 of 12 patients (83.3%) had complete clinical healing at 6 months		 [118]
8 Autologous-ADMSCs Perianal fistulizing CD group 1: 1 × 107 cells/ml. After 4 weeks, if safe,
group 2: 2 × 107 cells/ml. After 4 weeks, if safe,
group 3: 4 × 107 cells/ml		 I >9 8 weeks 2 patients in group 2 showed complete healing
and 3 patients in group 3 showed complete healing at week 8.		 [119]
9 Autologous-BMMSCs CD a single dose of
2 × 107, 5 × 107,
or 10 × 107 cells/kg intravenously		 I 12 2 weeks Single infusion of BMMSCs propagated ex vivo
using human platelet lysate-supplemented media
was safe and feasible at the doses of up to 10 million cells/kg		 [120]
10 Autologous-ADMSCs Perianal fistulizing CD 3 × 107 cells per centimeter length II 43 8 weeks 27/33 patients (82%) had complete fistula healing.
Of 27 patients, 23 patients (88%) sustained complete closure		 [121]